According to Danish biotechnology company Bavarian Nordic, the European Commission has approved its vaccine Imvanex for use in cases of monkeypox. "The European Commission has approved the company's smallpox vaccine, Imvanex, for the prevention of monkeypox," Bavarian Nordic said in its statement. will also be valid. Apart from the European Union, the US and Canada have also approved Imvanex for the prevention of monkeypox. Imvanex, originally intended to prevent smallpox disease, was first approved in the European Union in 2013. Meanwhile, during the increasing cases of monkeypox around the world, this vaccine was also found to be effective against monkeypox. It was only after this that Imvanex was approved as a treatment for monkeypox. Smallpox and monkeypox viruses have a lot in common, which is why Imvanex is proving to be effective. On Saturday, about 16,000 cases of monkeypox were reported in 72 countries. After this, the World Health Organization (WHO) put monkeypox in the category of global health emergency.
In May 2022, cases of monkeypox were reported in some countries in West and Central Africa. This virus-borne disease has now spread to Europe, America and Asia. According to WHO, monkeypox spreads from animal to human and from human to human. The disease spreads when it comes in contact with the skin of a person suffering from monkeypox. It can also spread through touching, clothing, sheets, pillows or utensils used by the victim. Symptoms for this disease can begin to emerge up to three weeks after coming into contact with an infected person. The first case of monkeypox in India came to light on 14 July in Kerala. Meanwhile, a suspicious case has also come up in Delhi.